β-Blocker use and diabetes symptom score: Results from the GEMINI study

Diabetes, Obesity and Metabolism

Volumn 9, Issue 3, 2007, Pages 408-417

  Mcgill, Janet B ^a   Bakris, G L ^b   Fonseca, V ^c   Raskin, P ^d   Messerli, F H ^e   Phillips, R A ^f   Katholi, R E ^g   Wright Jr , J T ^h   Iyengar, M ⁱ   Anderson, K M ⁱ   Lukas, M A ⁱ   Dalal, M R ⁱ   Bell, S H ^j  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g ST JOHN'S HOSPITAL   (United States)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁱ GLAXOSMITHKLINE   (United States)

^j University of Alabama at Birmingham   (United States)

more..

Author keywords

Carvedilol; Diabetes; Diabetes Symptom Checklist; Metoprolol tartrate; Quality of life; Symptom score

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIHYDROPYRIDINE DERIVATIVE; GLITAZONE DERIVATIVE; HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; HYPOGLYCEMIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCORING SYSTEM; SENSORY NEUROPATHY; SYMPTOM; VASODILATATION;

EID: 33947625081     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00693.x     Document Type: Article

References (31)

1. Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, Carretero-Ares JL, Arzua-Mouronte D, Herreros-Fernandez V. Health-related quality of life of subjects with known and unknown hypertension: Results from the population-based Hortega study. J Hypertens 2003; 21: 1283-1289.
2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206.
3. Cheng JW, Kalis MM, Feifer S. Patient-reported adherence to guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Pharmacotherapy 2001; 21: 828-841.
4. Snow V, Weiss KB, Mottur-Pilson C. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med 2003; 138: 587-592.
5. Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26: S80-S82.
6. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
7. Colucci WS. Landmark study: The Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN). Am J Cardiol 2004; 93: 13-16.
8. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.
9. UKPD Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713-720.
10. Majumdar SR. Beta-blockers for the treatment of hypertension in patients with diabetes: Exploring the contraindication myth. Cardiovasc Drugs Ther 1999; 13: 435-439.
11. Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 2004; 292: 2227-2236.
12. Bakris GL, Bell DS, Fonseca V et al. The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial. J Diabetes Complications 2005; 19: 74-79.
13. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM. Development of a type 2 diabetes symptom checklist: A measure of symptom severity. Diabet Med 1994; 11: 253-261.
14. Van der Does FE, De Neeling JN, Snoek FJ et al. Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care 1996; 19: 204-210.
15. Polonsky WH. Understanding and assessing diabetes-specific quality of life. Diabetes Spectr 2000; 13: 36.
16. Data on File. Philadelphia, PA: GlaxoSmithKline, 2006.
17. Bentler PM. Comparative fit indexes in structural models. Psychol Bull 1990; 107: 238-246.
18. Testa MA, Hollenberg NK, Anderson RB, Williams GH. Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system. Am J Hypertens 1991; 4: 363-373.
19. Adriaanse MC, Dekker JM, Spijkerman AM et al. Health-related quality of life in the first year following diagnosis of Type 2 diabetes: Newly diagnosed patients in general practice compared with screening-detected patients. The Hoorn Screening Study. Diabet Med 2004; 21: 1075-1081.
20. Adriaanse MC, Dekker JM, Spijkerman AM et al. Diabetes-related symptoms and negative mood in participants of a targeted population-screening program for type 2 diabetes: The Hoorn Screening Study. Qual Life Res 2005; 14: 1501-1509.
21. Merbis MA, Snoek FJ, Kanc K, Heine RJ. Hypoglycaemia induces emotional disruption. Patient Educ Couns 1996; 29: 117-122.
22. Van der Does FE, De Neeling JN, Snoek FJ et al. Randomized study of two different target levels of glycemic control within the acceptable range in type 2 diabetes. Effects on well-being at 1 year. Diabetes Care 1998; 21: 2085-2093.
23. Wee HL, Cheung YB, Li SC, Fong KY, Thumboo J. The impact of diabetes mellitus and other chronic medical conditions on health-related quality of life: Is the whole greater than the sum of its parts? Health Qual Life Outcomes 2005; 3: 2.
24. Glasgow RE, Ruggiero L, Eakin EG, Dryfoos J, Chobanian L. Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care 1997; 20: 562-567.
25. Ch YE, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: A critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12: 243-249.
26. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003; 26: 1408-1412.
27. Butler J, Khadim G, BeLue R et al. Tolerability to beta-blocker therapy among heart failure patients in clinical practice. J Card Fail 2003; 9: 203-209.
28. Bradford WD, Chen J, Krumholz HM. Under-utilisation of beta-blockers after acute myocardial infarction. Pharmacoeconomic implications. Pharmacoeconomics 1999; 15: 257-268.
29. VandenBurg MJ, Evans SJ, Cooper WD, Bradshaw F, Currie WJ. Is the feeling of cold extremities experienced by hypertensive patients due to their disease or their treatment? Eur J Clin Pharmacol 1984; 27: 47-49.
30. Ekbom T, Dahlof B, Hansson L, Lindholm LH, Schersten B, Wester PO. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: A report from the STOP-Hypertension study. J Hypertens 1992; 10: 1525-1530.
31. Rosen RC. Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Blood Press Suppl 1997; 1: 47-51.